Navigation Links
Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceutical's Brintellix Has Blockbuster Potential
Date:8/1/2013

BURLINGTON, Mass., Aug. 1, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that Lundbeck/Takeda Pharmaceutical's emerging antidepressant Brintellix will attain blockbuster status for unipolar depression* in the United States, France, Germany, Italy, Spain, United Kingdom and Japan by 2022. Brintellix is expected to be one of the most successful new agents in the unipolar depression market because of its potential for positive effects on cognition and its reasonably tolerable side effect profile demonstrated to date. Decision Resources expects Lundbeck and Takeda to position Brintellix as a first-line option for elderly patients with depression and as a second-line therapy in patients who fail a generic selective serotonin reuptake inhibitor (SSRI).

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

The Pharmacor advisory service entitled Unipolar Depression finds that major-market sales in the unipolar depression market will decline by 30 percent from 2012-2022 owing to the generic entry of the blockbuster drugs escitalopram (Lundbeck's Cipralex/Seroplex, other manufacturers, Forest Laboratories' Lexapro, generics; Lundbeck/Mochida Pharmaceuticals/Mitsubishi Tanabe Pharma's Lexapro), Bristol-Myers Squibb/Otsuka Pharmaceutical's Abilify and Eli Lilly/Shionogi's Cymbalta/Xeristar, as well as expanded generic competition for venlafaxine XR (Pfizer/Almirall's Effexor XR, other manufacturers, generics). The launch of Brintellix and two other emerging antidepressants by 2022—Eli Lilly's edivoxetine and Forest Laboratories/Pierre Fabre's Fetzima—will be insufficient to counteract this decline; edivoxetine and Fetzima will together reach just under $1 billion in sales across the major markets by 2022.

Furthermore, the atypical antipsychotic drug class will experience significant loss of sales in the unipolar depression market owing to continued generic erosion of key agents and, including generic competition to Abilify. Consequently, major-market sales of this drug class will drop by half, to just under $1 billion in 2022. The forecasted launch of Otsuka/Lundbeck's brexpiprazole and the expanded use of Dainippon Sumitomo Pharma/Sunovion/Takeda's Latuda across the major markets will only partially offset the forthcoming decline in drug class sales.

"In a highly genericized and fragmented market, in which SSRIs and serotonin and norepinephrine reuptake inhibitors (SNRIs) are and will remain deeply entrenched first-line agents, the uptake of emerging therapies among physicians will be highly dependent on their successful differentiation from currently available SSRIs and SNRIs," said Decision Resources Senior Business Insights Analyst Alana K. Simorellis, Ph.D. "An agent benefitting patients who fail to respond to current treatments or one that treats residual symptoms of depression represent opportunities for drug developers. An antidepressant or antipsychotic proven to be more effective in treatment-resistant patients would quickly gain physician acceptance and experience use, likely as part of an augmentation strategy."

*Unipolar depression encompasses major depressive disorder, minor depression and dysthymia.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Dr. Prem Reddy Named Among Most Influential Physician Executives in Nation
2. Brain Research Foundation Announces Grant To Study Concussive Events Among Grade School Children
3. Imaging Healthcare Specialists Among the First in the Nation to Offer Imaging Diagnosis for Alzheimers Disease
4. Advanced Radiology Among the First in the U.S. to Offer New Alzheimers Disease Tracer
5. Social Norms, Life Changes and Increasing Pressures Contribute to Substance Abuse Among Adult Women
6. Frost & Sullivan: Miniaturization of Medical Devices Reduces Mortality Rates among Cardiac Dysrhythmia Patients
7. Takedas Deerfield Campus Ranked Among Chicagos Top 100 Workplaces in 2012
8. CBIS Releases Corporate Operational Guidance for 2013 as the Company Reorganizes to better meet the Growing Global Crisis Associated with Anti-Retroviral Drug Resistance among People with AIDS, as well as the Increasing Need for Patient Friendly Ski
9. Forbes Ranks SynCardia Among "Americas Most Promising Companies" for Second Straight Year
10. GNC NutriWater, COTYs Beyonce Pulse NYC, Swansons Super DPA Fish Oil, Among First SupplySide Insights Awards Finalists
11. Poorest U.S. States Rank Among Most Wasteful in Unnecessary Medication-Related Costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... Nov 30, 2016 Research and Markets has ... Monitoring Devices 2017 - MedCore" report to their offering. ... , , ... the skull. In healthy individuals, it is circulated though the brain and ... where the amount of CSF surrounding the brain changes significantly. ...
(Date:11/30/2016)... Research and Markets has announced the addition of the ... their offering. ... Detachable coil embolization is a minimally invasive method ... embolization treatment of cerebral aneurysms is less invasive and requires less recovery ... wall of an artery in the brain. This area bulges in the ...
(Date:11/30/2016)... Calif. , Nov. 30, 2016 Varian ... it was named America,s Most JUST Company in the ... and Forbes magazine,s inaugural "JUST 100 List." ... of the largest surveys ever conducted on attitudes towards ... months. This inaugural list ranks U.S companies against their ...
Breaking Medicine Technology:
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ... proudly announces the launch of its 60-day free trial program for all of ... shipping make the offer a truly hassle free experience. , FlexiSpot’s unique desktop ...
(Date:12/2/2016)... ... 02, 2016 , ... With the number of pain management programs available for ... find the one that works for them. When an inventor from Suisun City, Calif., ... and decided to share it with others. , He developed a prototype for PRO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is proud to ... which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that are helping ... prolonging life 6 years in the last 3 decades,” says Dr. Valentine Fuster, ...
(Date:12/2/2016)... ... , ... Sourced from the Isbre Springs beneath the 5,000 year old Hardanger ... of just 6 ppm TDS (Total Dissolved Solids) in addition to its excellent taste ... several ShopRite and FoodTown stores in NJ and received rave comments from consumers. , ...
(Date:12/2/2016)... Francisco, CA (PRWEB) , ... December 02, 2016 ... ... digitally-enabled care journeys, announced today that it has raised $6.0 million in an ... inspired by Clarify Health’s conviction that patients and their caregivers can receive far ...
Breaking Medicine News(10 mins):